The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. The metric has seen a significant loss of -15.28% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -0.07%. Over the past 30 days, the price of BMRN has leaped by -3.30%. And in the last five days, it has fallen by -3.03%.
The current stock price for BioMarin Pharmaceutical Inc. (BMRN) is $87.68. The stock experienced a significant increase during the last trading session, reaching $92.48 after opening at $91.99. It dipped to a low of $87.60 before ultimately closing at $91.62.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
BioMarin Pharmaceutical Inc.’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $117.77 on 01/27/23, with the lowest value being $80.53 on 11/09/22.
52-week price history of BMRN Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. BioMarin Pharmaceutical Inc.’s current trading price is -25.55% away from its 52-week high, while its distance from the 52-week low is 8.88%. The stock’s price range over this timeframe has been between $80.53 and $117.77. The shares of the Healthcare sector company recorded a trading volume of approximately 1.41 million for the day, which was comparatively higher than the average daily volume of 1.27 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
BioMarin Pharmaceutical Inc. (BMRN) has experienced a quarterly decline of -7.13% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 16.54B and boasts a workforce of 3082 employees.
Expert Opinions: Analysts’ Ratings for BioMarin Pharmaceutical Inc.
As of right now, 15 analysts are rating BioMarin Pharmaceutical Inc. as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 8 analysts are recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 90.99, with a change in price of -9.83. Similarly, BioMarin Pharmaceutical Inc. recorded 1,185,434 in trading volume during the last 100 days, posting a change of -10.08%.
BMRN’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for BMRN stands at 0.23. Similarly, the long-term debt-to-equity ratio is also 0.23.
BMRN Stock Stochastic Average
BioMarin Pharmaceutical Inc.’s raw stochastic average for the past 50 days is currently at 33.95%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 1.06%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 34.14% and 39.52%, respectively.
